Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: Results from a large tertiary laboratory in Australia
•Overall, 9.3% of the tested Nocardia spp. isolates displayed sulfonamide resistance.•N. farcinica accounted for the highest number of sulfonamide-resistant strains.•59.3% of Nocardia were imipenem-resistant; high imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern.•A high leve...
Saved in:
Published in | Journal of global antimicrobial resistance. Vol. 20; pp. 110 - 117 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.03.2020
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Overall, 9.3% of the tested Nocardia spp. isolates displayed sulfonamide resistance.•N. farcinica accounted for the highest number of sulfonamide-resistant strains.•59.3% of Nocardia were imipenem-resistant; high imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern.•A high level of intermediate resistance to tetracyclines was observed in most species.•Linezolid and amikacin remain good empirical options for nocardiosis treatment.
There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South Wales. This study aimed to investigate the species distribution and antimicrobial susceptibility of a large number of contemporary (2011–2016) clinical Nocardia spp. referred to a large tertiary hospital in Sydney, Australia.
A total of 270Nocardia spp. isolates identified to species level by dual-target gene sequencing were investigated. Antimicrobial susceptibility testing was performed using a Sensititre™ RAPMYCOI panel, with the minimum inhibitory concentration (MIC) range and geometric mean MIC obtained for each species and drug combination. Antimicrobial susceptibility profiles and species distribution were analysed.
The respiratory system is the most affected site in nocardiosis. In this study, Nocardia nova complex was the most frequently isolated Nocardia spp. (n = 80; 29.6%), followed by Nocardia cyriacigeorgica (n = 61; 22.6%), Nocardia brasiliensis (n = 52; 19.3%) and Nocardia farcinica (n = 38; 14.1%). Of the tested isolates, 9.3% and 59.3% displayed resistance to trimethoprim/sulfamethoxazole (SXT) and imipenem, respectively. Nocardia farcinica accounted for the highest number of SXT-resistant isolates. High imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern but has been reported elsewhere. All tested isolates remained susceptible to linezolid, with only 0.7% exhibiting resistance to amikacin.
Linezolid and amikacin remain good empirical options for treatment of nocardiosis. Routine antimicrobial susceptibility testing ofNocardia is advisable with the detection of sulfonamide resistance and atypical antibiograms in this study. |
---|---|
AbstractList | Objectives: There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South Wales. This study aimed to investigate the species distribution and antimicrobial susceptibility of a large number of contemporary (2011–2016) clinical Nocardia spp. referred to a large tertiary hospital in Sydney, Australia. Methods: A total of 270Nocardia spp. isolates identified to species level by dual-target gene sequencing were investigated. Antimicrobial susceptibility testing was performed using a Sensititre™ RAPMYCOI panel, with the minimum inhibitory concentration (MIC) range and geometric mean MIC obtained for each species and drug combination. Antimicrobial susceptibility profiles and species distribution were analysed. Results: The respiratory system is the most affected site in nocardiosis. In this study, Nocardia nova complex was the most frequently isolated Nocardia spp. (n = 80; 29.6%), followed by Nocardia cyriacigeorgica (n = 61; 22.6%), Nocardia brasiliensis (n = 52; 19.3%) and Nocardia farcinica (n = 38; 14.1%). Of the tested isolates, 9.3% and 59.3% displayed resistance to trimethoprim/sulfamethoxazole (SXT) and imipenem, respectively. Nocardia farcinica accounted for the highest number of SXT-resistant isolates. High imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern but has been reported elsewhere. All tested isolates remained susceptible to linezolid, with only 0.7% exhibiting resistance to amikacin. Conclusion: Linezolid and amikacin remain good empirical options for treatment of nocardiosis. Routine antimicrobial susceptibility testing ofNocardia is advisable with the detection of sulfonamide resistance and atypical antibiograms in this study. OBJECTIVESThere are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South Wales. This study aimed to investigate the species distribution and antimicrobial susceptibility of a large number of contemporary (2011-2016) clinical Nocardia spp. referred to a large tertiary hospital in Sydney, Australia. METHODSA total of 270Nocardia spp. isolates identified to species level by dual-target gene sequencing were investigated. Antimicrobial susceptibility testing was performed using a Sensititre™ RAPMYCOI panel, with the minimum inhibitory concentration (MIC) range and geometric mean MIC obtained for each species and drug combination. Antimicrobial susceptibility profiles and species distribution were analysed. RESULTSThe respiratory system is the most affected site in nocardiosis. In this study, Nocardia nova complex was the most frequently isolated Nocardia spp. (n = 80; 29.6%), followed by Nocardia cyriacigeorgica (n = 61; 22.6%), Nocardia brasiliensis (n = 52; 19.3%) and Nocardia farcinica (n = 38; 14.1%). Of the tested isolates, 9.3% and 59.3% displayed resistance to trimethoprim/sulfamethoxazole (SXT) and imipenem, respectively. Nocardia farcinica accounted for the highest number of SXT-resistant isolates. High imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern but has been reported elsewhere. All tested isolates remained susceptible to linezolid, with only 0.7% exhibiting resistance to amikacin. CONCLUSIONLinezolid and amikacin remain good empirical options for treatment of nocardiosis. Routine antimicrobial susceptibility testing ofNocardia is advisable with the detection of sulfonamide resistance and atypical antibiograms in this study. •Overall, 9.3% of the tested Nocardia spp. isolates displayed sulfonamide resistance.•N. farcinica accounted for the highest number of sulfonamide-resistant strains.•59.3% of Nocardia were imipenem-resistant; high imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern.•A high level of intermediate resistance to tetracyclines was observed in most species.•Linezolid and amikacin remain good empirical options for nocardiosis treatment. There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South Wales. This study aimed to investigate the species distribution and antimicrobial susceptibility of a large number of contemporary (2011–2016) clinical Nocardia spp. referred to a large tertiary hospital in Sydney, Australia. A total of 270Nocardia spp. isolates identified to species level by dual-target gene sequencing were investigated. Antimicrobial susceptibility testing was performed using a Sensititre™ RAPMYCOI panel, with the minimum inhibitory concentration (MIC) range and geometric mean MIC obtained for each species and drug combination. Antimicrobial susceptibility profiles and species distribution were analysed. The respiratory system is the most affected site in nocardiosis. In this study, Nocardia nova complex was the most frequently isolated Nocardia spp. (n = 80; 29.6%), followed by Nocardia cyriacigeorgica (n = 61; 22.6%), Nocardia brasiliensis (n = 52; 19.3%) and Nocardia farcinica (n = 38; 14.1%). Of the tested isolates, 9.3% and 59.3% displayed resistance to trimethoprim/sulfamethoxazole (SXT) and imipenem, respectively. Nocardia farcinica accounted for the highest number of SXT-resistant isolates. High imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern but has been reported elsewhere. All tested isolates remained susceptible to linezolid, with only 0.7% exhibiting resistance to amikacin. Linezolid and amikacin remain good empirical options for treatment of nocardiosis. Routine antimicrobial susceptibility testing ofNocardia is advisable with the detection of sulfonamide resistance and atypical antibiograms in this study. There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South Wales. This study aimed to investigate the species distribution and antimicrobial susceptibility of a large number of contemporary (2011-2016) clinical Nocardia spp. referred to a large tertiary hospital in Sydney, Australia. A total of 270Nocardia spp. isolates identified to species level by dual-target gene sequencing were investigated. Antimicrobial susceptibility testing was performed using a Sensititre™ RAPMYCOI panel, with the minimum inhibitory concentration (MIC) range and geometric mean MIC obtained for each species and drug combination. Antimicrobial susceptibility profiles and species distribution were analysed. The respiratory system is the most affected site in nocardiosis. In this study, Nocardia nova complex was the most frequently isolated Nocardia spp. (n = 80; 29.6%), followed by Nocardia cyriacigeorgica (n = 61; 22.6%), Nocardia brasiliensis (n = 52; 19.3%) and Nocardia farcinica (n = 38; 14.1%). Of the tested isolates, 9.3% and 59.3% displayed resistance to trimethoprim/sulfamethoxazole (SXT) and imipenem, respectively. Nocardia farcinica accounted for the highest number of SXT-resistant isolates. High imipenem resistance in N. cyriacigeorgica is atypical to its drug pattern but has been reported elsewhere. All tested isolates remained susceptible to linezolid, with only 0.7% exhibiting resistance to amikacin. Linezolid and amikacin remain good empirical options for treatment of nocardiosis. Routine antimicrobial susceptibility testing ofNocardia is advisable with the detection of sulfonamide resistance and atypical antibiograms in this study. |
Author | Halliday, Catriona L. Tan, Yen Ee Chen, Sharon C.-A. |
Author_xml | – sequence: 1 givenname: Yen Ee surname: Tan fullname: Tan, Yen Ee email: tan.yen.ee@singhealth.com.sg organization: Department of Microbiology, Singapore General Hospital, 20 College Road, 169856, Singapore – sequence: 2 givenname: Sharon C.-A. surname: Chen fullname: Chen, Sharon C.-A. organization: Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research (ICPMR), New South Wales Health Pathology, Westmead Hospital, Westmead, NSW, Australia – sequence: 3 givenname: Catriona L. surname: Halliday fullname: Halliday, Catriona L. organization: Clinical Mycology Reference Laboratory, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute for Clinical Pathology and Medical Research (ICPMR), New South Wales Health Pathology, Westmead Hospital, Westmead, NSW, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31400449$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUhSNUREvpC7BAXrKZ4J_EThCbUcVPpQokBGvrxr4ZOXLiwXYqzbvwsPUw7SzxxtfWuefa53tdXSxhwap6y2jNKJMfpnraQaw5ZX1NZU1Z96K64pyJjWJKXJxr2V5WNylNtKy-YVyqV9WlYA2lTdNfVX-3S3azMzEMDjxJazK4z25w3uUD2ccwOo-JwGJJ2qNxpbYu5eiGNbuwkDCSGa0z4P2BRPT4AEsm34OBaB0893wkPzGtPicyxjATIB7iDknGmB3EQzkOIUIOpXQL2a5lAHgHb6qXI_iEN0_7dfX7y-dft9829z--3t1u7zemFTxvutaCaTkzgxGqHZVpBts3Qo1SdYhsgE7xoZWMGTBD03MjO8MsilGInnPLxHV1d_K1ASa9j24uj9IBnP53EeJOQ3mp8ahHYRFQceh72fSqBamsMEy0naSMCyhe709eJbs_K6asZ1cy9R4WDGvSnCvWNUzSvkj5SVrSTynieB7NqD5C1pM-QtZHyJpKXSCXpndP_utQkj-3PCMtgk8nAZbEHhxGnQqCxRRKEU0uX3L_838Ez8e9lg |
CitedBy_id | crossref_primary_10_11150_kansenshogakuzasshi_96_106 crossref_primary_10_1186_s12941_024_00677_4 crossref_primary_10_3390_antibiotics11101438 crossref_primary_10_1016_j_ijid_2023_02_023 crossref_primary_10_1159_000508717 crossref_primary_10_1371_journal_pntd_0011432 crossref_primary_10_1097_MOT_0000000000000793 crossref_primary_10_3201_eid2811_220262 crossref_primary_10_3390_microorganisms12061156 crossref_primary_10_3390_pathogens10050579 crossref_primary_10_1016_j_jfma_2022_06_011 crossref_primary_10_1109_TCBB_2020_3046557 crossref_primary_10_1093_jac_dkad236 crossref_primary_10_1093_jac_dkad299 crossref_primary_10_5582_ddt_2021_01035 crossref_primary_10_1099_jmm_0_001581 crossref_primary_10_1080_09546634_2023_2229467 crossref_primary_10_1128_spectrum_01560_21 crossref_primary_10_12677_MD_2023_133046 crossref_primary_10_1186_s12866_021_02412_x crossref_primary_10_1186_s12879_023_08067_5 crossref_primary_10_1016_j_bjid_2023_102806 crossref_primary_10_1016_j_idcr_2022_e01668 crossref_primary_10_1016_j_jmii_2022_11_002 crossref_primary_10_1111_imj_16234 crossref_primary_10_1007_s10096_022_04542_0 crossref_primary_10_1016_j_eimce_2021_02_014 crossref_primary_10_1097_IPC_0000000000001313 crossref_primary_10_1128_aac_01890_21 crossref_primary_10_3390_pathogens12010068 crossref_primary_10_1016_j_eimc_2021_02_010 crossref_primary_10_1016_j_pathol_2023_03_008 |
Cites_doi | 10.1128/AAC.45.4.1295-1297.2001 10.1128/AAC.02770-14 10.1128/AAC.32.12.1776 10.5694/j.1326-5377.1992.tb121509.x 10.1128/JCM.01419-17 10.1128/AAC.01537-17 10.1093/ofid/ofw208 10.1128/AAC.01531-13 10.2174/1874285800903010097 10.1128/JCM.43.6.2624-2628.2005 10.1016/j.diagmicrobio.2013.05.008 10.1128/AAC.01808-10 10.1128/AAC.00135-12 10.1016/j.diagmicrobio.2016.09.024 10.1128/AAC.01102-06 10.1128/JCM.00155-06 10.1016/j.jgar.2018.06.021 10.1016/j.ijantimicag.2016.07.005 10.1093/cid/ciq255 10.1016/j.mayocp.2011.11.016 10.1016/j.clinmicnews.2015.01.007 10.1086/657399 10.1007/s15010-009-9193-9 10.1097/MD.0000000000005255 |
ContentType | Journal Article |
Copyright | 2019 International Society for Antimicrobial Chemotherapy Copyright © 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2019 International Society for Antimicrobial Chemotherapy – notice: Copyright © 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved. |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1016/j.jgar.2019.06.018 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Open Access: DOAJ - Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2213-7173 |
EndPage | 117 |
ExternalDocumentID | oai_doaj_org_article_f3deae72a9964975a67d3c135860123a 10_1016_j_jgar_2019_06_018 31400449 S2213716519301626 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Australia |
GeographicLocations_xml | – name: Australia |
GroupedDBID | --M .1- .FO .~1 0R~ 1~. 4.4 457 4G. 53G 6I. 7-5 8P~ AAAJQ AABSN AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAXUO ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE AEBSH AEKER AENEX AFCTW AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CJTIS COPKO EBS EFJIC EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA GROUPED_DOAJ HVGLF HZ~ KOM LCYCR LUGTX M41 MO0 NCXOZ O-L O9- OAUVE OK1 P-8 P-9 PC. Q38 RIG ROL SDF SPCBC SSH SSI SSZ T5K Z5R ~G- 0SF AAQFI AAXKI ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c532t-85dac521cbc375f7c4bd9437f678ee1ba872b5611cacb492c68c1de3f33922d13 |
IEDL.DBID | DOA |
ISSN | 2213-7165 |
IngestDate | Tue Oct 22 15:09:38 EDT 2024 Tue Dec 03 23:45:41 EST 2024 Thu Nov 21 20:59:05 EST 2024 Sat Sep 28 08:24:49 EDT 2024 Fri Feb 23 02:48:19 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Medically relevant Nocardia Species distribution Australia Susceptibility |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c532t-85dac521cbc375f7c4bd9437f678ee1ba872b5611cacb492c68c1de3f33922d13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/f3deae72a9964975a67d3c135860123a |
PMID | 31400449 |
PQID | 2271841609 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f3deae72a9964975a67d3c135860123a proquest_miscellaneous_2271841609 crossref_primary_10_1016_j_jgar_2019_06_018 pubmed_primary_31400449 elsevier_sciencedirect_doi_10_1016_j_jgar_2019_06_018 |
PublicationCentury | 2000 |
PublicationDate | March 2020 2020-03-00 20200301 2020-03-01 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: March 2020 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of global antimicrobial resistance. |
PublicationTitleAlternate | J Glob Antimicrob Resist |
PublicationYear | 2020 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | Wilson (bib0005) 2012; 87 Rafiei, Peri, Righi, Harris, Paterson (bib0060) 2016; 95 Lai, Liu, Ko, Chen, Tang, Huang (bib0115) 2011; 55 Conville, Zelazny, Witebsky (bib0075) 2006; 44 Uhde, Pathak, McCullum, Jannat‐Khah, Shadomy, Dykewicz (bib0045) 2010; 51 Georghiou, Blacklock (bib0065) 1992; 156 Wallace, Steele, Sumter, Smith (bib0120) 1988; 32 Chen, Lu, Huang, Lu, Liau, Lin (bib0100) 2013; 77 Montravers, Bassetti, Dupont, Eckmann, Heizmann, Guirao (bib0130) 2013; 68 Girard, Mailler, Polsinelli, Jacob, Saccomani, Celliere (bib0150) 2017; 87 Farooqui, Irfan, Shakoor, Zafar (bib0030) 2018; 15 Clinical and Laboratory Standards Institute (CLSI) (bib0080) 2011 Pea, Cojutti, Pagotto, Cristini, Furlanut, Viale (bib0135) 2012; 56 Clinical and Laboratory Standards Institute (CLSI) (bib0025) 2018 Valdezate, Garrido, Carrasco, Medina-Pascual, Villalón, Navarro (bib0090) 2017; 72 Brown-Elliott, Ward, Crist, Mann, Wilson, Wallace (bib0140) 2001; 45 Kong, Chen, Chen, Sintchenko, Halliday, Cai (bib0070) 2009; 3 Brown-Elliott, Conville, Wallace (bib0010) 2015; 37 McGuinness, Whiting, Baird, Currie, Ralph, Anstey (bib0055) 2016; 3 Schlaberg, Fisher, Hanson (bib0125) 2014; 58 McTaggart, Doucet, Witkowska, Richardsona (bib0105) 2015; 59 List of prokaryotic names with standing in nomenclature. Conville, Brown-Elliott, Smith, Zelazny (bib0015) 2018; 56 Antibiotic Expert Groups (bib0035) 2014 Cercenado, Marín, Sánchez-Martínez, Cuevas, Martínez-Alarcón, Bouza (bib0110) 2007; 51 Wauters, Avesani, Charlier, Janssens, Vaneechoutte, Delmée (bib0095) 2005; 43 Ambrosioni, Lew, Garbino (bib0040) 2010; 38 Halliday, Chen, Kidd, van Hal, Chapman, Heath (bib0085) 2016; 48 Lai, Liu, Ko, Chen, Tang, Huang (bib0050) 2011; 52 Brown-Elliott, Wallace (bib0145) 2017; 61 [Accessed 13 January 2019]. Lai (10.1016/j.jgar.2019.06.018_bib0050) 2011; 52 Valdezate (10.1016/j.jgar.2019.06.018_bib0090) 2017; 72 Antibiotic Expert Groups (10.1016/j.jgar.2019.06.018_bib0035) 2014 Montravers (10.1016/j.jgar.2019.06.018_bib0130) 2013; 68 Chen (10.1016/j.jgar.2019.06.018_bib0100) 2013; 77 Rafiei (10.1016/j.jgar.2019.06.018_bib0060) 2016; 95 Wilson (10.1016/j.jgar.2019.06.018_bib0005) 2012; 87 Brown-Elliott (10.1016/j.jgar.2019.06.018_bib0140) 2001; 45 Conville (10.1016/j.jgar.2019.06.018_bib0075) 2006; 44 Conville (10.1016/j.jgar.2019.06.018_bib0015) 2018; 56 Kong (10.1016/j.jgar.2019.06.018_bib0070) 2009; 3 Pea (10.1016/j.jgar.2019.06.018_bib0135) 2012; 56 Brown-Elliott (10.1016/j.jgar.2019.06.018_bib0145) 2017; 61 McGuinness (10.1016/j.jgar.2019.06.018_bib0055) 2016; 3 McTaggart (10.1016/j.jgar.2019.06.018_bib0105) 2015; 59 Brown-Elliott (10.1016/j.jgar.2019.06.018_bib0010) 2015; 37 Wallace (10.1016/j.jgar.2019.06.018_bib0120) 1988; 32 10.1016/j.jgar.2019.06.018_bib0020 Ambrosioni (10.1016/j.jgar.2019.06.018_bib0040) 2010; 38 Clinical and Laboratory Standards Institute (CLSI) (10.1016/j.jgar.2019.06.018_bib0080) 2011 Clinical and Laboratory Standards Institute (CLSI) (10.1016/j.jgar.2019.06.018_bib0025) 2018 Wauters (10.1016/j.jgar.2019.06.018_bib0095) 2005; 43 Uhde (10.1016/j.jgar.2019.06.018_bib0045) 2010; 51 Cercenado (10.1016/j.jgar.2019.06.018_bib0110) 2007; 51 Lai (10.1016/j.jgar.2019.06.018_bib0115) 2011; 55 Halliday (10.1016/j.jgar.2019.06.018_bib0085) 2016; 48 Schlaberg (10.1016/j.jgar.2019.06.018_bib0125) 2014; 58 Farooqui (10.1016/j.jgar.2019.06.018_bib0030) 2018; 15 Girard (10.1016/j.jgar.2019.06.018_bib0150) 2017; 87 Georghiou (10.1016/j.jgar.2019.06.018_bib0065) 1992; 156 |
References_xml | – start-page: 283e4 year: 2014 ident: bib0035 article-title: Therapeutic guidelines: antibiotic. Version 15 contributor: fullname: Antibiotic Expert Groups – volume: 87 start-page: 7 year: 2017 end-page: 10 ident: bib0150 article-title: Routine identification of publication-title: Diagn Microbiol Infect Dis contributor: fullname: Celliere – volume: 156 start-page: 692 year: 1992 end-page: 697 ident: bib0065 article-title: Infection with publication-title: Med J Aust contributor: fullname: Blacklock – volume: 58 start-page: 795 year: 2014 end-page: 800 ident: bib0125 article-title: Susceptibility profiles of publication-title: Antimicrob Agents Chemother contributor: fullname: Hanson – volume: 68 start-page: ii15 year: 2013 end-page: 24 ident: bib0130 article-title: Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies publication-title: J Antimicrob Chemother contributor: fullname: Guirao – volume: 32 start-page: 1776 year: 1988 end-page: 1779 ident: bib0120 article-title: Antimicrobial susceptibility patterns of Nocardia asteroides publication-title: Antimicrob Agents Chemother contributor: fullname: Smith – volume: 45 start-page: 1295 year: 2001 end-page: 1297 ident: bib0140 article-title: In vitro activities of linezolid against multiple publication-title: Antimicrob Agents Chemother contributor: fullname: Wallace – volume: 56 start-page: pii: 1417 year: 2018 end-page: 9 ident: bib0015 article-title: The complexities of publication-title: J Clin Microbiol contributor: fullname: Zelazny – volume: 3 start-page: ofw208 year: 2016 ident: bib0055 article-title: Nocardiosis in the tropical Northern Territory of Australia, 1997–2014 publication-title: Open Forum Infect Dis contributor: fullname: Anstey – volume: 59 start-page: 269 year: 2015 end-page: 275 ident: bib0105 article-title: Antimicrobial susceptibility among clinical publication-title: Antimicrob Agents Chemother contributor: fullname: Richardsona – volume: 51 start-page: 1445 year: 2010 end-page: 1448 ident: bib0045 article-title: Antimicrobial‐resistant publication-title: Clin Infect Dis contributor: fullname: Dykewicz – volume: 48 start-page: 453 year: 2016 end-page: 458 ident: bib0085 article-title: Antifungal susceptibilities of non- publication-title: Int J Antimicrob Agents contributor: fullname: Heath – year: 2018 ident: bib0025 article-title: Interpretative criteria for identification of bacteria and fungi by targeted DNA sequencing contributor: fullname: Clinical and Laboratory Standards Institute (CLSI) – volume: 3 start-page: 97 year: 2009 end-page: 105 ident: bib0070 article-title: Assignment of reference 5ʹ-end 16S rDNA sequences and species-specific sequence polymorphisms improves species identification of Nocardia publication-title: Open Microbiol J contributor: fullname: Cai – volume: 61 year: 2017 ident: bib0145 article-title: In vitro susceptibility testing of tedizolid against isolates of Nocardia publication-title: Antimicrob Agents Chemother contributor: fullname: Wallace – volume: 37 start-page: 25 year: 2015 end-page: 32 ident: bib0010 article-title: Current status of publication-title: Clin Microbiol Newsl contributor: fullname: Wallace – volume: 51 start-page: 1102 year: 2007 end-page: 1104 ident: bib0110 article-title: In vitro activities of tigecycline and eight other antimicrobials against different publication-title: Antimicrob Agents Chemother contributor: fullname: Bouza – volume: 87 start-page: 403 year: 2012 end-page: 407 ident: bib0005 article-title: Nocardiosis: updates and clinical overview publication-title: Mayo Clin Proc contributor: fullname: Wilson – volume: 38 start-page: 89 year: 2010 end-page: 97 ident: bib0040 article-title: Nocardiosis: updated clinical review and experience at a tertiary centre publication-title: Infection contributor: fullname: Garbino – volume: 77 start-page: 74 year: 2013 end-page: 78 ident: bib0100 article-title: Cutaneous manifestations of publication-title: Diagn Microbiol Infect Dis contributor: fullname: Lin – volume: 95 start-page: e5255 year: 2016 ident: bib0060 article-title: Central nervous system nocardiosis in Queensland: a report of 20 cases and review of the literature publication-title: Med (Baltimore) contributor: fullname: Paterson – volume: 43 start-page: 2624 year: 2005 end-page: 2628 ident: bib0095 article-title: Distribution of publication-title: J Clin Microbiol contributor: fullname: Delmée – volume: 55 start-page: 2084 year: 2011 end-page: 2091 ident: bib0115 article-title: Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various publication-title: Antimicrob Agents Chemother contributor: fullname: Huang – year: 2011 ident: bib0080 article-title: Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard—second edition contributor: fullname: Clinical and Laboratory Standards Institute (CLSI) – volume: 44 start-page: 2760 year: 2006 end-page: 2766 ident: bib0075 article-title: Analysis of publication-title: J Clin Microbiol contributor: fullname: Witebsky – volume: 72 start-page: 754 year: 2017 end-page: 761 ident: bib0090 article-title: Epidemiology and susceptibility to antimicrobial agents of the main publication-title: J Antimicrob Chemother contributor: fullname: Navarro – volume: 15 start-page: 219 year: 2018 end-page: 221 ident: bib0030 article-title: Antimicrobial susceptibility and clinical characteristics of publication-title: J Glob Antimicrob Resist contributor: fullname: Zafar – volume: 52 start-page: 1472 year: 2011 end-page: 1473 ident: bib0050 article-title: Antimicrobial-resistant publication-title: Clin Infect Dis contributor: fullname: Huang – volume: 56 year: 2012 ident: bib0135 article-title: Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy publication-title: Antimicrob Agents Chemother contributor: fullname: Viale – year: 2018 ident: 10.1016/j.jgar.2019.06.018_bib0025 contributor: fullname: Clinical and Laboratory Standards Institute (CLSI) – volume: 45 start-page: 1295 year: 2001 ident: 10.1016/j.jgar.2019.06.018_bib0140 article-title: In vitro activities of linezolid against multiple Nocardia species publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.45.4.1295-1297.2001 contributor: fullname: Brown-Elliott – volume: 59 start-page: 269 year: 2015 ident: 10.1016/j.jgar.2019.06.018_bib0105 article-title: Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02770-14 contributor: fullname: McTaggart – volume: 32 start-page: 1776 year: 1988 ident: 10.1016/j.jgar.2019.06.018_bib0120 article-title: Antimicrobial susceptibility patterns of Nocardia asteroides publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.32.12.1776 contributor: fullname: Wallace – volume: 156 start-page: 692 year: 1992 ident: 10.1016/j.jgar.2019.06.018_bib0065 article-title: Infection with Nocardia species in Queensland. A review of 102 clinical isolates publication-title: Med J Aust doi: 10.5694/j.1326-5377.1992.tb121509.x contributor: fullname: Georghiou – volume: 56 start-page: pii: 1417 year: 2018 ident: 10.1016/j.jgar.2019.06.018_bib0015 article-title: The complexities of Nocardia taxonomy and identification publication-title: J Clin Microbiol doi: 10.1128/JCM.01419-17 contributor: fullname: Conville – volume: 61 year: 2017 ident: 10.1016/j.jgar.2019.06.018_bib0145 article-title: In vitro susceptibility testing of tedizolid against isolates of Nocardia publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01537-17 contributor: fullname: Brown-Elliott – volume: 3 start-page: ofw208 year: 2016 ident: 10.1016/j.jgar.2019.06.018_bib0055 article-title: Nocardiosis in the tropical Northern Territory of Australia, 1997–2014 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofw208 contributor: fullname: McGuinness – volume: 58 start-page: 795 year: 2014 ident: 10.1016/j.jgar.2019.06.018_bib0125 article-title: Susceptibility profiles of Nocardia isolates based on current taxonomy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01531-13 contributor: fullname: Schlaberg – volume: 3 start-page: 97 year: 2009 ident: 10.1016/j.jgar.2019.06.018_bib0070 article-title: Assignment of reference 5ʹ-end 16S rDNA sequences and species-specific sequence polymorphisms improves species identification of Nocardia publication-title: Open Microbiol J doi: 10.2174/1874285800903010097 contributor: fullname: Kong – volume: 43 start-page: 2624 year: 2005 ident: 10.1016/j.jgar.2019.06.018_bib0095 article-title: Distribution of Nocardia species in clinical samples and their routine rapid identification in the laboratory publication-title: J Clin Microbiol doi: 10.1128/JCM.43.6.2624-2628.2005 contributor: fullname: Wauters – volume: 77 start-page: 74 year: 2013 ident: 10.1016/j.jgar.2019.06.018_bib0100 article-title: Cutaneous manifestations of Nocardia brasiliensis infection in Taiwan during 2002–2012—clinical studies and molecular typing of pathogen by gyrB and 16S gene sequencing publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2013.05.008 contributor: fullname: Chen – start-page: 283e4 year: 2014 ident: 10.1016/j.jgar.2019.06.018_bib0035 contributor: fullname: Antibiotic Expert Groups – volume: 55 start-page: 2084 year: 2011 ident: 10.1016/j.jgar.2019.06.018_bib0115 article-title: Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01808-10 contributor: fullname: Lai – volume: 56 year: 2012 ident: 10.1016/j.jgar.2019.06.018_bib0135 article-title: Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00135-12 contributor: fullname: Pea – volume: 87 start-page: 7 year: 2017 ident: 10.1016/j.jgar.2019.06.018_bib0150 article-title: Routine identification of Nocardia species by MALDI-TOF mass spectrometry publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2016.09.024 contributor: fullname: Girard – volume: 51 start-page: 1102 year: 2007 ident: 10.1016/j.jgar.2019.06.018_bib0110 article-title: In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01102-06 contributor: fullname: Cercenado – volume: 44 start-page: 2760 year: 2006 ident: 10.1016/j.jgar.2019.06.018_bib0075 article-title: Analysis of secA1 gene sequences for identification of Nocardia species publication-title: J Clin Microbiol doi: 10.1128/JCM.00155-06 contributor: fullname: Conville – volume: 68 start-page: ii15 issue: Suppl. 2 year: 2013 ident: 10.1016/j.jgar.2019.06.018_bib0130 article-title: Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies publication-title: J Antimicrob Chemother contributor: fullname: Montravers – volume: 15 start-page: 219 year: 2018 ident: 10.1016/j.jgar.2019.06.018_bib0030 article-title: Antimicrobial susceptibility and clinical characteristics of Nocardia isolates from a tertiary care centre diagnostic laboratory in Pakistan publication-title: J Glob Antimicrob Resist doi: 10.1016/j.jgar.2018.06.021 contributor: fullname: Farooqui – volume: 48 start-page: 453 year: 2016 ident: 10.1016/j.jgar.2019.06.018_bib0085 article-title: Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2016.07.005 contributor: fullname: Halliday – volume: 52 start-page: 1472 year: 2011 ident: 10.1016/j.jgar.2019.06.018_bib0050 article-title: Antimicrobial-resistant Nocardia isolates, Taiwan, 1998–2009 publication-title: Clin Infect Dis doi: 10.1093/cid/ciq255 contributor: fullname: Lai – volume: 87 start-page: 403 year: 2012 ident: 10.1016/j.jgar.2019.06.018_bib0005 article-title: Nocardiosis: updates and clinical overview publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2011.11.016 contributor: fullname: Wilson – volume: 37 start-page: 25 year: 2015 ident: 10.1016/j.jgar.2019.06.018_bib0010 article-title: Current status of Nocardia taxonomy and recommended identification methods publication-title: Clin Microbiol Newsl doi: 10.1016/j.clinmicnews.2015.01.007 contributor: fullname: Brown-Elliott – year: 2011 ident: 10.1016/j.jgar.2019.06.018_bib0080 contributor: fullname: Clinical and Laboratory Standards Institute (CLSI) – volume: 51 start-page: 1445 year: 2010 ident: 10.1016/j.jgar.2019.06.018_bib0045 article-title: Antimicrobial‐resistant Nocardia isolates, United States, 1995–2004 publication-title: Clin Infect Dis doi: 10.1086/657399 contributor: fullname: Uhde – volume: 38 start-page: 89 year: 2010 ident: 10.1016/j.jgar.2019.06.018_bib0040 article-title: Nocardiosis: updated clinical review and experience at a tertiary centre publication-title: Infection doi: 10.1007/s15010-009-9193-9 contributor: fullname: Ambrosioni – volume: 95 start-page: e5255 year: 2016 ident: 10.1016/j.jgar.2019.06.018_bib0060 article-title: Central nervous system nocardiosis in Queensland: a report of 20 cases and review of the literature publication-title: Med (Baltimore) doi: 10.1097/MD.0000000000005255 contributor: fullname: Rafiei – volume: 72 start-page: 754 year: 2017 ident: 10.1016/j.jgar.2019.06.018_bib0090 article-title: Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain publication-title: J Antimicrob Chemother contributor: fullname: Valdezate – ident: 10.1016/j.jgar.2019.06.018_bib0020 |
SSID | ssj0000941267 |
Score | 2.35587 |
Snippet | •Overall, 9.3% of the tested Nocardia spp. isolates displayed sulfonamide resistance.•N. farcinica accounted for the highest number of sulfonamide-resistant... There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New South... OBJECTIVESThere are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of New... Objectives: There are limited surveillance studies on the epidemiology and resistance rates ofNocardia spp. in Australia, particularly in the jurisdiction of... |
SourceID | doaj proquest crossref pubmed elsevier |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 110 |
SubjectTerms | Amikacin - pharmacology Anti-Infective Agents - pharmacology Australia Drug Resistance, Bacterial Epidemiological Monitoring Humans Imipenem - pharmacology Laboratories Medically relevant Nocardia Microbial Sensitivity Tests Nocardia - classification Nocardia - drug effects Nocardia - isolation & purification Nocardia Infections - drug therapy Nocardia Infections - microbiology Respiratory System - microbiology Species distribution Susceptibility Tertiary Care Centers Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology |
SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection 2013 dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhEOil9N3tI6jQW3E3etiWektCQyg0h7aB3ISsR3HY2GHtPeylv6Q_tjOyvCSH9tCbEZJlpLHmk_TNfIS8D7WOCAMKFkMspGausNGHIujggpKR2aQZ-fWiOr-UX67Kqz1yOsfCIK0yr_3Tmp5W61yyzKO5vG3b5XfOmQC0jxAEcAvHtNuyPEIVg4-_2O6cBbYvjCchWaxfYIMcOzPRvK4x2St4QZ3SeKL2xx3_lNL433NTf4OhyR2dPSIPM46kx9OnPiZ7oXtCDiZlye1T8vu4G9ubNmVZgmrDZkj0lcSE3dIs1D1Q23mKsZawXaYeU-hm9SvaR3ozXeGsthR1VQBwj_QCHB8a1NzmE_0Whs1qHChGqVBLV8grp0gzaO16S7OF9fDYdnR3rPKMXJ59_nF6XmQhhsKVgo-FKr114Odd40RdxtrJxmsp6gieLgTWWFXzBoAYc9Y1UnNXKcd8EFEA-uKeiedkv-u78JLQSmvOvAiOSSe5F1o1dV1aBzBJOVWpBfkwD7-5nfJtmJmIdm1wsgxOlkE2HoPaJzhDu5qYKzsV9OufJhuLicIHG2puYWsnNXRW1V44JkpVIaC0C1LO82vumR68qv1n5-9mYzDwT-JFi-1CvxkM5-DxAeke6QV5MVnJ7hMFw1VT6lf_2etr8oDjlj_R4N6Q_XG9CW8BF43NYTL8P7eeDaw priority: 102 providerName: Elsevier |
Title | Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: Results from a large tertiary laboratory in Australia |
URI | https://dx.doi.org/10.1016/j.jgar.2019.06.018 https://www.ncbi.nlm.nih.gov/pubmed/31400449 https://search.proquest.com/docview/2271841609 https://doaj.org/article/f3deae72a9964975a67d3c135860123a |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLVgEBIbxJvyqIzEDgXGjyQ2u4IYFRBdIEaaneX4IaXqpGiSLrrhS_hY7rWTqiyADbsochLL9ybnOD6-h5CXodYRaUDBYoiF1MwVNvpQBB1cUDIymzwjv6yq5bn8dFFeHFl9oSYslwfOA_cmCh9sqLkFYi51Xdqq9sIxUaoK6UCmRqf8aDK1zno5xpN9LOdMFDApKMcdM1nctcYSr4B9OhXvRMePI1RKxft_A6c_kc8EQmd3yO2RPdJF7vVdci1098jN7Ce5v09-LrqhvWxTbSVo1u_6JFpJ-tc9He25e2o7T3GHJUySqcfCuaPnFd1GepkXbjZ7im4qQLMHugK4wzSarnlLv4Z-txl6intTqKUbVJNTFBe09mpPx7zawmHb0cPPlAfk_OzDt_fLYrRfKFwp-FCo0lsH6O4aJ-oy1k42XktRR8C3EFhjVc0boF_MWddIzV2lHPNBRAGci3smHpKTbtuFx4RWWnPmRXBMOsm90KqpIZQOyJFyqlIz8moafvM9V9kwk_xsbTBYBoNlUIPHoPU7jNChJVbITicgb8yYN-ZfeTMj5RRfM5KNTCLgVu1fH_5iSgYDbyIur9gubHe94RxwHvjtqZ6RRzlLDl0UDL-VUj_5H11_Sm5xnPUnJdwzcjJc7cJzoEZDMyfXX_9gc3Jj8fHzcjVP78QvuP4PRg |
link.rule.ids | 314,780,784,864,2102,4502,24116,27924,27925,45585,45679 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYJLxZstLyNxQ2HrRx7mViqqBdo9QCv1Zjl-oFTbbLXJHvbCL-HHMuM4K3qAA7fIsmPLHs98Y3-eIeStL1VAGJCx4EMmFbOZCc5nXnnrKxmYiTkjT-fF7Fx-ucgvdsjR-BYGaZVJ9w86PWrrVDJNszm9bprpd86ZALSPEARwCy9ukdsyB_QLQv3-J9setID_wnjMJIsNMmyRHs8MPK9LjPYKZlDFOJ6Y_OMPAxXj-N-wU3_DodEeHd8newlI0sNhrA_Ijm8fkjtDasnNI_LrsO2bqyaGWYJq3bqL_JVIhd3QlKm7o6Z1FB9bgr9MHcbQTemv6DLQq-EOZ7GhmFgFEHdP52D5UKLGNh_oN9-tF31H8ZkKNXSBxHKKPIPGrDY0idgSPpuWbs9VHpPz409nR7MsZWLIbC54n1W5MxYMva2tKPNQWlk7JUUZwNR5z2pTlbwGJMassbVU3BaVZc6LIAB-ccfEE7LbLlv_jNBCKc6c8JZJK7kTqqrLMjcWcFJlq6KakHfj9OvrIeCGHplolxoXS-NiaaTjMaj9EVdoWxODZceC5eqHTtKig3De-JIb8O2kgs6K0gnLRF4ViCjNhOTj-uobsge_av7Z-ZtRGDRsSrxpMa1frjvNOZh8gLoHakKeDlKyHaJgqDal2v_PXl-Tu7Oz0xN98nn-9Tm5x9H_j5y4F2S3X639SwBJff0qboLfZ90Q1w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+susceptibility+profiles+and+species+distribution+of+medically+relevant+Nocardia+species%3A+Results+from+a+large+tertiary+laboratory+in+Australia&rft.jtitle=Journal+of+global+antimicrobial+resistance.&rft.au=Tan%2C+Yen+Ee&rft.au=Chen%2C+Sharon+C.-A.&rft.au=Halliday%2C+Catriona+L.&rft.date=2020-03-01&rft.issn=2213-7165&rft.volume=20&rft.spage=110&rft.epage=117&rft_id=info:doi/10.1016%2Fj.jgar.2019.06.018&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jgar_2019_06_018 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2213-7165&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2213-7165&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2213-7165&client=summon |